AXGN Overview

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.

Wall Street analysts forecast AXGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXGN is39.80 USD with a low forecast of 39.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

AxoGen Inc revenue for the last quarter amounts to 61.46M USD, increased 26.56

AxoGen Inc. EPS for the last quarter amounts to -0.38 USD, increased 375.00

AxoGen Inc (AXGN) has 622 emplpoyees as of May 23 2026.

Today AXGN has the market capitalization of 2.27B USD.